CIPH Ciphergen Biosystems (MM)

Ciphergen Introduces Deep Proteome(TM) Research Services at American Society of Mass Spectrometry Annual Meeting New Equalizer(TM) Technology Uses Combinatorial Bead Peptide Libraries to Enrich Low Abundant Proteins and Enable Exploration of Trace Proteins in Complex Proteomes FREMONT, Calif., June 6 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) today announced the introduction of Deep Proteome(TM) Research Services, making proprietary Equalizer(TM) protein biomarker discovery technology available to scientists for the first time. These services will be preferentially provided to Ciphergen's ProteinChip System customers. Equalizer technology utilizes novel combinatorial peptide ligand libraries synthesized on beads to compress the dynamic range of protein concentrations by several orders of magnitude while maintaining the diversity and differential levels of expression of the proteome and enabling the detection of trace proteins. Discovery of low abundance proteins in various proteomes constitutes a major problem in biology research and biomarker discovery. The main options available today to overcome this problem are based on depletion of highly abundant proteins. These methods result in the loss of associated proteins, involve laborious, multi-step methods that are not suited for high throughput, require large sample volumes, and may dilute trace proteins. Equalizer Beads simultaneously lower the concentration of high abundance proteins and enrich the concentration of low trace proteins without depletion of any specific proteins, in a high throughput manner. When used together with Ciphergen's new, automated MultiSelect(TM) protein profiling technology, trace protein detection and total protein count are dramatically improved. "The Equalizer(TM) technology has been received with great excitement by the scientific community. We are convinced that this technology is a major breakthrough in proteomics. Our Deep Proteome Research Services will enable scientists to look at low abundance proteins in various biological samples and significantly improve their biomarker discovery power," commented Martin Verhoef, President of Ciphergen's Biosystems Division. About Ciphergen Ciphergen's Diagnostics Division is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Centers(R) for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen's Biosystems Division develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research, and process proteomics applications. ProteinChip Systems enable protein discovery, characterization, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the use of Deep Proteome Services to look at low abundance proteins in various proteomes and significantly improve biomarker discovery, the diagnostic tests that Ciphergen Diagnostics is developing, the predictive diagnostic value of protein biomarkers, and the expectation that protein multi-marker tests will improve patient care. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the ability of Equalizer Technology to discover scientifically useful biomarkers, the ProteinChip technology's ability to successfully discover, validate and assay biomarkers and patterns of biomarkers that have diagnostic utility, and our ability to protect and promote our proprietary technologies. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q dated May 10, 2005, for further information regarding these and other risks of the Company's business. NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc., +1-510-505 2297 Web site: http://www.ciphergen.com/

Copyright